The DOI matches its Crossref record; 265 of the 265 references it cites were found in a registry or an index.
HDACs and HDAC Inhibitors in Cancer Development and Therapy
Open accessAbstract
Over the last several decades, it has become clear that epigenetic abnormalities may be one of the hallmarks of cancer. Posttranslational modifications of histones, for example, may play a crucial role in cancer development and progression by modulating gene transcription, chromatin remodeling, and nuclear architecture. Histone acetylation, a well-studied posttranslational histone modification, is controlled by the opposing activities of histone acetyltransferases (HATs) and histone deacetylases (HDACs). By removing acetyl groups, HDACs reverse chromatin acetylation and alter transcription of oncogenes and tumor suppressor genes. In addition, HDACs deacetylate numerous nonhistone cellular substrates that govern a wide array of biological processes including cancer initiation and progression. This review will discuss the role of HDACs in cancer and the therapeutic potential of HDAC inhibitors (HDACi) as emerging drugs in cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
RETRACTED: Human SIRT6 Promotes DNA End Resection Through CtIP Deacetylation
Kaidi, A., Weinert, B. T., Choudhary, C., & Jackson, S. P. (2010) · Science · doi:10.1126/science.1192049 · Cited by 366
RetractedZhou, S., Zhou, Z.-W., Li, X.-X., He, Z., Pan, S., Yang, Y.-X., Zhang, X., Chew, K., Yang, T., Qiu, J., et al. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s75976 · Cited by 103
RetractedLysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase
Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S.-I., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,659
Negative Control of p53 by Sir2α Promotes Cell Survival under Stress
Luo, J., Nikolaev, A. Y., Imai, S.-I., Chen, D., Su, F., Shiloh, A., Guarente, L., & Gu, W. (2001) · Cell · doi:10.1016/s0092-8674(01)00524-4 · Cited by 2,081
Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
Seto, E., & Yoshida, M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018713 · Cited by 1,989
Self-citationFraga, M. F., Ballestar, E., Villar-Garea, A., Boix-Chornet, M., Espada, J., Schotta, G., Bonaldi, T., Haydon, C., Ropero, S., Petrie, K., et al. (2005) · Nature Genetics · doi:10.1038/ng1531 · Cited by 1,923
Genomic Instability and Aging-like Phenotype in the Absence of Mammalian SIRT6
Mostoslavsky, R., Chua, K. F., Lombard, D. B., Pang, W. W., Fischer, M. R., Gellon, L., Liu, P., Mostoslavsky, G., Franco, S., Murphy, M. M., et al. (2006) · Cell · doi:10.1016/j.cell.2005.11.044 · Cited by 1,637
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy
Lee, I. H., Cao, L., Mostoslavsky, R., Lombard, D. B., Liu, J., Bruns, N. E., Tsokos, M., Alt, F. W., & Finkel, T. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712145105 · Cited by 1,476
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1247 · Cited by 1,365
HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS.
Pandey, U. B., Nie, Z., Batlevi, Y., McCray, B. A., Ritson, G. P., Nedelsky, N. B., Schwartz, S. L., DiProspero, N. A., Knight, M. A., Schuldiner, O., et al. (2007) · Nature · doi:10.1038/nature05853 · Cited by 1,234
Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0430973100 · Cited by 1,066
SIRT6 Promotes DNA Repair Under Stress by Activating PARP1
Mao, Z., Hine, C., Tian, X., Van Meter, M., Au, M., Vaidya, A., Seluanov, A., & Gorbunova, V. (2011) · Science · doi:10.1126/science.1202723 · Cited by 867
Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A
Butler, K. V., Kalin, J., Brochier, C., Vistoli, G., Langley, B., & Kozikowski, A. P. (2010) · Journal of the American Chemical Society · doi:10.1021/ja102758v · Cited by 801
Impaired DNA Damage Response, Genome Instability, and Tumorigenesis in SIRT1 Mutant Mice
Wang, R.-H., Sengupta, K., Li, C., Kim, H.-S., Cao, L., Xiao, C., Kim, S., Xu, X., Zheng, Y., Chilton, B., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.09.001 · Cited by 769
Sirtuin 1 Modulates Cellular Responses to Hypoxia by Deacetylating Hypoxia-Inducible Factor 1α
Lim, J.-H., Lee, Y.-M., Chun, Y.-S., Chen, J., Kim, J.-E., & Park, J.-W. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.023 · Cited by 758
HDAC6 controls autophagosome maturation essential for ubiquitin‐selective quality‐control autophagy
Lee, J., Koga, H., Kawaguchi, Y., Tang, W., Wong, E., Gao, Y., Pandey, U. B., Kaushik, S., Tresse, E., Lu, J., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2009.405 · Cited by 756
(2002) · PubMed · Cited by 732
Chemical phylogenetics of histone deacetylases
Bradner, J. E., West, N., Grachan, M. L., Greenberg, E. F., Haggarty, S. J., Warnow, T., & Mazitschek, R. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.313 · Cited by 720
Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors
Khan, N., Jeffers, M., Kumar, S., Hackett, C., Boldog, F., Khramtsov, N., Qian, X., Mills, E., Berghs, S. C., Carey, N., et al. (2008) · Biochemical Journal · doi:10.1042/bj20070779 · Cited by 713
Juergens, R. A., Wrangle, J., Vendetti, F. P., Murphy, S. C., Zhao, M., Coleman, B., Sebree, R., Rodgers, K., Hooker, C. M., Franco, N., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0214 · Cited by 686
Deacetylation of Nuclear LC3 Drives Autophagy Initiation under Starvation
Huang, R., Xu, Y., Wan, W., Shou, X., Qian, J., You, Z., Liu, B., Chang, C., Zhou, T., Lippincott-Schwartz, J., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2014.12.013 · Cited by 662
Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes
Bantscheff, M., Hopf, C., Savitski, M. M., Dittmann, A., Grandi, P., Michon, A.-M., Schlegl, J., Abraham, Y., Becher, I., Bergamini, G., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1759 · Cited by 659
Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining
Miller, K. M., Tjeertes, J. V., Coates, J., Legube, G., Polo, S. E., Britton, S., & Jackson, S. P. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1899 · Cited by 629
Santo, L., Hideshima, T., Kung, A. L., Tseng, J.-C., Tamang, D., Yang, M., Jarpe, M., van Duzer, J. H., Mazitschek, R., Ogier, W. C., et al. (2012) · Blood · doi:10.1182/blood-2011-10-387365 · Cited by 616
Lee, J.-Y., Nagano, Y., Taylor, J. P., Lim, K. L., & Yao, T.-P. (2010) · Journal of Cell Biology · doi:10.1083/jcb.201001039 · Cited by 520
Ungerstedt, J. S., Sowa, Y., Xu, W.-S., Shao, Y., Dokmanovic, M., Perez, G., Ngo, L., Holmgren, A., Jiang, X., & Marks, P. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408732102 · Cited by 503
Weichert, W., Röske, A., Gekeler, V, Beckers, T., Stephan, C., Jung, K., Fritzsche, F. R., Niesporek, S., Denkert, C., Dietel, M., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604199 · Cited by 477
Balasubramanian, S., Ramos, J., Luo, W., Sirisawad, M., Verner, E., & Buggy, J. J. (2008) · Leukemia · doi:10.1038/leu.2008.9 · Cited by 458
SIRT3 deacetylates FOXO3 to protect mitochondria against oxidative damage
Tseng, A. H. H., Shieh, S.-S., & Wang, D. L. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.05.002 · Cited by 452
Bradbury, C. A., Khanim, F. L., Hayden, R., Bunce, C. M., White, D. A., Drayson, M. T., Craddock, C., & Turner, B. M. (2005) · Leukemia · doi:10.1038/sj.leu.2403910 · Cited by 404
Histone deacetylase 8 in neuroblastoma tumorigenesis
Oehme, I., Deubzer, H. E., Wegener, D., Pickert, D., Linke, J.-P., Hero, B., Kopp-Schneider, A., Westermann, F., Ulrich, S. M., von Deimling, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0684 · Cited by 398
HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner
Malvaez, M., McQuown, S. C., Rogge, G. A., Astarabadi, M., Jacques, V., Carreiro, S., Rusche, J. R., & Wood, M. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213364110 · Cited by 395
Munster, P. N., Thurn, K. T., Thomas, S., Raha, P., Lacevic, M., Miller, A., Melisko, M., Ismail-Khan, R., Rugo, H., Moasser, M., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.156 · Cited by 391
Shi, Y., Dong, M., Hong, X., Zhang, W., Feng, J., Zhu, J., Yu, L., Ke, X., Huang, H., Shen, Z., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv237 · Cited by 385
SIRT6 recruits SNF2H to DNA break sites, preventing genomic instability through chromatin remodeling
Toiber, D., Erdel, F., Bouazoune, K., Silberman, D. M., Zhong, L., Mulligan, P., Sebastian, C., Cosentino, C., Martinez-Pastor, B., Giacosa, S., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.06.018 · Cited by 381
Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group
Lobera, M., Madauss, K. P., Pohlhaus, D. T., Wright, Q. G., Trocha, M., Schmidt, D. R., Baloglu, E., Trump, R. P., Head, M. S., Hofmann, G. A., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1223 · Cited by 376
Weichert, W., Röske, A., Niesporek, S., Noske, A., Buckendahl, A.-C., Dietel, M., Gekeler, V., Boehm, M., Beckers, T., & Denkert, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0990 · Cited by 361
Weichert, W., Röske, A., Gekeler, V., Beckers, T., Ebert, M. P., Pross, M., Dietel, M., Denkert, C., & Röcken, C. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70004-4 · Cited by 360
von Burstin, J., Eser, S., Paul, M. C., Seidler, B., Brandl, M., Messer, M., von Werder, A., Schmidt, A., Mages, J., Pagel, P., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.004 · Cited by 356
Hdac3 is essential for the maintenance of chromatin structure and genome stability
Bhaskara, S., Knutson, S. K., Jiang, G., Chandrasekharan, M. B., Wilson, A. J., Zheng, S., Yenamandra, A., Locke, K., Yuan, J.-L., Bonine-Summers, A. R., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.022 · Cited by 353
Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases
Hu, E., Dul, E., Sung, C.-M., Chen, Z., Kirkpatrick, R., Zhang, G.-F., Johanson, K., Liu, R., Lago, A., Hofmann, G., et al. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.055541 · Cited by 347
Ou, X., Lee, M. R., Huang, X., Messina‐Graham, S., & Broxmeyer, H. E. (2014) · STEM CELLS · doi:10.1002/stem.1641 · Cited by 336
Byles, V, Zhu, L., Lovaas, J. D., Chmilewski, L. K., Wang, J., Faller, D. V., & Dai, Y. (2012) · Oncogene · doi:10.1038/onc.2011.612 · Cited by 309
Quantitation of HDAC1 mRNA Expression in Invasive Carcinoma of the Breast*
Zhang, Z., Yamashita, H., Toyama, T., Sugiura, H., Ando, Y., Mita, K., Hamaguchi, M., Hara, Y., Kobayashi, S., & Iwase, H. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-6001-1 · Cited by 305
HDAC6 Expression Is Correlated with Better Survival in Breast Cancer
Zhang, Z., Yamashita, H., Toyama, T., Sugiura, H., Omoto, Y., Ando, Y., Mita, K., Hamaguchi, M., Hayashi, S.-I., & Iwase, H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0455 · Cited by 293
Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression
Yamaguchi, T., Cubizolles, F., Zhang, Y., Reichert, N., Kohler, H., Seiser, C., & Matthias, P. (2010) · Genes & Development · doi:10.1101/gad.552310 · Cited by 291
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition
Ropero, S., Fraga, M. F., Ballestar, E., Hamelin, R., Yamamoto, H., Boix-Chornet, M., Caballero, R., Alaminos, M., Setien, F., Paz, M. F., et al. (2006) · Nature Genetics · doi:10.1038/ng1773 · Cited by 290
Aghdassi, A., Sendler, M., Guenther, A., Mayerle, J., Behn, C.-O., Heidecke, C.-D., Friess, H., Büchler, M., Evert, M., Lerch, M. M., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300060 · Cited by 289
Fiskus, W., Sharma, S., Shah, B., Portier, B. P., Devaraj, S. G. T., Liu, K., Iyer, S. P., Bearss, D., & Bhalla, K. N. (2014) · Leukemia · doi:10.1038/leu.2014.119 · Cited by 284
SirT3 Regulates the Mitochondrial Unfolded Protein Response
Papa, L., & Germain, D. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01337-13 · Cited by 281
Acetylation site specificities of lysine deacetylase inhibitors in human cells
Schölz, C., Weinert, B. T., Wagner, S. A., Beli, P., Miyake, Y., Qi, J., Jensen, L. J., Streicher, W., McCarthy, A. R., Westwood, N. J., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3130 · Cited by 275
Clinical and Experimental Applications of Sodium Phenylbutyrate
Iannitti, T., & Palmieri, B. (2011) · Drugs in R & D · doi:10.1007/bf03259725 · Cited by 270
Cai, X., Zhai, H.-X., Wang, J., Forrester, J., Qu, H., Yin, L., Lai, C.-J., Bao, R., & Qian, C. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901453q · Cited by 264
Eades, G., Yao, Y., Yang, M., Zhang, Y., Chumsri, S., & Zhou, Q. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.229401 · Cited by 263
Kong, X., Lin, Z., Liang, D., Fath, D., Sang, N., & Caro, J. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.6.2019-2028.2006 · Cited by 258
Müller, B. M., Jana, L., Kasajima, A., Lehmann, A., Prinzler, J., Budczies, J., Winzer, K.-J., Dietel, M., Weichert, W., & Denkert, C. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-215 · Cited by 256
Role for Histone Deacetylase 1 in Human Tumor Cell Proliferation
Senese, S., Zaragoza, K., Minardi, S., Muradore, I., Ronzoni, S., Passafaro, A., Bernard, L., Draetta, G. F., Alcalay, M., Seiser, C., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00494-07 · Cited by 254
SIRT1 contributes to telomere maintenance and augments global homologous recombination
Palacios, J. A., Herranz, D., De Bonis, M. L., Velasco, S., Serrano, M., & Blasco, M. A. (2010) · Journal of Cell Biology · doi:10.1083/jcb.201005160 · Cited by 253
Qian, C., Lai, C.-J., Bao, R., Wang, D.-G., Wang, J., Xu, G.-X., Atoyan, R., Qu, H., Yin, L., Samson, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0055 · Cited by 248
Prebet, T., Sun, Z., Figueroa, M. E., Ketterling, R., Melnick, A., Greenberg, P. L., Herman, J., Juckett, M., Wang, E. S., Smith, M. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.3102 · Cited by 246
Stark, M., & Hayward, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4152 · Cited by 237
Meidhof, S., Brabletz, S., Lehmann, W., Preca, B., Mock, K., Ruh, M., Schüler, J., Berthold, M., Weber, A., Burk, U., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404396 · Cited by 229
Histone deacetylase 10 promotes autophagy-mediated cell survival
Oehme, I., Linke, J.-P., Böck, B. C., Milde, T., Lodrini, M., Hartenstein, B., Wiegand, I., Eckert, C., Roth, W., Kool, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300113110 · Cited by 221
SIRT1 Suppresses the Epithelial-to-Mesenchymal Transition in Cancer Metastasis and Organ Fibrosis
Simic, P., Williams, E. O., Bell, E. L., Gong, J. J., Bonkowski, M., & Guarente, L. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.03.019 · Cited by 221
Histone deacetylase inhibitors and cell death
Zhang, J., & Zhong, Q. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1656-6 · Cited by 214
Osada, H., Tatematsu, Y., Saito, H., Yatabe, Y., Mitsudomi, T., & Takahashi, T. (2004) · International Journal of Cancer · doi:10.1002/ijc.20395 · Cited by 213
Buurman, R., Gürlevik, E., Schäffer, V., Eilers, M., Sandbothe, M., Kreipe, H., Wilkens, L., Schlegelberger, B., Kühnel, F., & Skawran, B. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.033 · Cited by 211
Tong, Z.-T., Cai, M.-Y., Wang, X.-G., Kong, L.-L., Mai, S.-J., Liu, Y.-H., Zhang, H.-B., Liao, Y.-J., Zheng, F., Zhu, W., et al. (2012) · Oncogene · doi:10.1038/onc.2011.254 · Cited by 210
Moreno, D. A., Scrideli, C. A., Cortez, M. A. A., De Paula Queiroz, R., Valera, E. T., Da Silva Silveira, V., Yunes, J. A., Brandalise, S. R., & Tone, L. G. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08301.x · Cited by 208
Lachenmayer, A., Toffanin, S., Cabellos, L., Alsinet, C., Hoshida, Y., Villanueva, A., Minguez, B., Tsai, H.-W., Ward, S. C., Thung, S., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.01.009 · Cited by 205
Dowling, D. P., Gantt, S. L., Gattis, S. G., Fierke, C. A., & Christianson, D. W. (2008) · Biochemistry · doi:10.1021/bi801610c · Cited by 200
Yoo, Y., Kong, G., & Lee, M. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601025 · Cited by 200
HDAC4 Protein Regulates HIF1α Protein Lysine Acetylation and Cancer Cell Response to Hypoxia
Geng, H., Harvey, C. T., Pittsenbarger, J., Liu, Q., Beer, T. M., Xue, C., & Qian, D. Z. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.257055 · Cited by 197
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial
Younes, A., Oki, Y., Bociek, R. G., Kuruvilla, J., Fanale, M., Neelapu, S., Copeland, A., Buglio, D., Galal, A., Besterman, J., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70265-0 · Cited by 196
Kato, H., Tamamizu-Kato, S., & Shibasaki, F. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406320200 · Cited by 196
Class IIb HDAC6 regulates endothelial cell migration and angiogenesis by deacetylation of cortactin
Kaluza, D., Kroll, J., Gesierich, S., Yao, T., Boon, R. A., Hergenreider, E., Tjwa, M., Rössig, L., Seto, E., Augustin, H. G., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.298 · Cited by 196
Self-citationBergman, J. A., Woan, K., Perez-Villarroel, P., Villagra, A., Sotomayor, E. M., & Kozikowski, A. P. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301098e · Cited by 195
Milde, T., Oehme, I., Korshunov, A., Kopp-Schneider, A., Remke, M., Northcott, P., Deubzer, H. E., Lodrini, M., Taylor, M. D., von Deimling, A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0395 · Cited by 193
Design and evaluation of ‘Linkerless’ hydroxamic acids as selective HDAC8 inhibitors
KrennHrubec, K., Marshall, B. L., Hedglin, M., Verdin, E., & Ulrich, S. M. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.02.064 · Cited by 192
Methot, J. L., Chakravarty, P. K., Chenard, M., Close, J., Cruz, J. C., Dahlberg, W. K., Fleming, J., Hamblett, C. L., Hamill, J. E., Harrington, P., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.12.031 · Cited by 191
Mai, A., Massa, S., Pezzi, R., Simeoni, S., Rotili, D., Nebbioso, A., Scognamiglio, A., Altucci, L., Loidl, P., & Brosch, G. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049002a · Cited by 184
Weichert, W., Denkert, C., Noske, A., Darb-Esfahani, S., Dietel, M., Kalloger, S. E., Huntsman, D. G., & Köbel, M. (2008) · Neoplasia · doi:10.1593/neo.08474 · Cited by 180
Rettig, I., Koeneke, E., Trippel, F., Mueller, W. C., Burhenne, J., Kopp-Schneider, A., Fabian, J., Schober, A., Fernekorn, U., von Deimling, A., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.24 · Cited by 180
Takasaka, N., Araya, J., Hara, H., Ito, S., Kobayashi, K., Kurita, Y., Wakui, H., Yoshii, Y., Yumino, Y., Fujii, S., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302341 · Cited by 180
Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response
Kao, G. D., McKenna, W. G., Guenther, M. G., Muschel, R. J., Lazar, M. A., & Yen, T. J. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200209065 · Cited by 179
Marek, L., Hamacher, A., Hansen, F. K., Kuna, K., Gohlke, H., Kassack, M. U., & Kurz, T. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301254q · Cited by 177
HDAC4-Regulated STAT1 Activation Mediates Platinum Resistance in Ovarian Cancer
Stronach, E. A., Alfraidi, A., Rama, N., Datler, C., Studd, J. B., Agarwal, R., Guney, T. G., Gourley, C., Hennessy, B. T., Mills, G. B., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4111 · Cited by 176
A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity
Li, Y., Kao, G. D., Garcia, B. A., Shabanowitz, J., Hunt, D. F., Qin, J., Phelan, C., & Lazar, M. A. (2006) · Genes & Development · doi:10.1101/gad.1455006 · Cited by 176
Self-citationDysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma
Mithraprabhu, S., Kalff, A., Chow, A., Khong, T., & Spencer, A. (2014) · Epigenetics · doi:10.4161/15592294.2014.983367 · Cited by 175
Histone Deacetylases: A Saga of Perturbed Acetylation Homeostasis in Cancer
Parbin, S., Kar, S., Shilpi, A., Sengupta, D., Deb, M., Rath, S. K., & Patra, S. K. (2014) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155413506582 · Cited by 172
HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA
Fritsche, P., Seidler, B., Schüler, S., Schnieke, A., Göttlicher, M., Schmid, R. M., Saur, D., & Schneider, G. (2009) · Gut · doi:10.1136/gut.2009.180711 · Cited by 167
Suzuki, T., Ota, Y., Ri, M., Bando, M., Gotoh, A., Itoh, Y., Tsumoto, H., Tatum, P. R., Mizukami, T., Nakagawa, H., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300837y · Cited by 165
Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer
Fritzsche, F. R., Weichert, W., Röske, A., Gekeler, V., Beckers, T., Stephan, C., Jung, K., Scholman, K., Denkert, C., Dietel, M., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-381 · Cited by 163
Li, Z., & Zhu, W.-G. (2014) · International Journal of Biological Sciences · doi:10.7150/ijbs.9067 · Cited by 160
Histone deacetylase 3 as a novel therapeutic target in multiple myeloma
Minami, J., Suzuki, R., Mazitschek, R., Gorgun, G., Ghosh, B., Cirstea, D., Hu, Y., Mimura, N., Ohguchi, H., Cottini, F., et al. (2014) · Leukemia · doi:10.1038/leu.2013.231 · Cited by 159
Conti, C., Leo, E., Eichler, G. S., Sordet, O., Martin, M. M., Fan, A. M., Aladjem, M. I., & Pommier, Y. G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3028 · Cited by 159
Reid, T., Valone, F., Lipera, W., Irwin, D., Paroly, W., Natale, R., Sreedharan, S., Keer, H., Lum, B., Scappaticci, F., et al. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2004.03.002 · Cited by 159
Urbich, C., Rössig, L., Kaluza, D., Potente, M., Boeckel, J., Knau, A., Diehl, F., Geng, J.-G., Hofmann, W., Zeiher, A. M., et al. (2009) · Blood · doi:10.1182/blood-2009-01-196485 · Cited by 157
Negative regulation of histone deacetylase 8 activity by cyclic AMP-dependent protein kinase A
Lee, H., Rezai-Zadeh, N., & Seto, E. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.2.765-773.2004 · Cited by 153
HDAC6 Deacetylates and Ubiquitinates MSH2 to Maintain Proper Levels of MutSα
Zhang, M., Xiang, S., Joo, H.-Y., Wang, L., Williams, K. A., Liu, W., Hu, C., Tong, D., Haakenson, J., Wang, C., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.04.028 · Cited by 151 · cited 3×
“MutS protein homolog 2 (MSH2), a key DNA mismatch repair protein, is regulated by class IIb HDACs.”
Self-citationHistone deacetylase inhibitors in hematological malignancies and solid tumors
Chun, P. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0571-1 · Cited by 151
Histone deacetylases 1 and 2 regulate autophagy flux and skeletal muscle homeostasis in mice
Moresi, V., Carrer, M., Grueter, C. E., Rifki, O. F., Shelton, J. M., Richardson, J. A., Bassel‐Duby, R., & Olson, E. N. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121159109 · Cited by 151
Schroeder, F. A., Lewis, M. C., Fass, D. M., Wagner, F. F., Zhang, Y.-L., Hennig, K. M., Gale, J., Zhao, W.-N., Reis, S., Barker, D. D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071323 · Cited by 146
Hayashi, A., Horiuchi, A., Kikuchi, N., Hayashi, T., Fuseya, C., 鈴木, 昭., Konishi, I., & Shiozawa, T. (2010) · International Journal of Cancer · doi:10.1002/ijc.25151 · Cited by 146
Gupta, M., Han, J. J., Stenson, M. J., Wellik, L. E., & Witzig, T. E. (2011) · Leukemia · doi:10.1038/leu.2011.340 · Cited by 146
Zupkovitz, G., Grausenburger, R., Brunmeir, R., Senese, S., Tischler, J., Jurkin, J., Rembold, M., Meunier, D., Egger, G., Lagger, S., et al. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01500-09 · Cited by 146
Development of a histone deacetylase 6 inhibitor and its biological effects
Lee, J.-H., Mahendran, A., Yao, Y., Ngo, L., Venta-Perez, G., Choy, M. L., Kim, N., Ham, W.-S., Breslow, R., & Marks, P. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313893110 · Cited by 141
Minamiya, Y., Ono, T., Saito, H., Takahashi, N., Ito, M., Mitsui, M., Motoyama, S., & Ogawa, J. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.02.019 · Cited by 138
An intact immune system is required for the anticancer activities of histone deacetylase inhibitors
West, A. C., Mattarollo, S. R., Shortt, J., Cluse, L. A., Christiansen, A. J., Smyth, M. J., & Johnstone, R. W. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0890 · Cited by 137
Histone deacetylase 1, 2, 6 and acetylated histone H4 in B‐ and T‐cell lymphomas
Marquard, L., Poulsen, C. B., Gjerdrum, L. M. R., Brown, P. D. N., Christensen, I. J., Jensen, P. B., Sehested, M., Johansen, P., & Ralfkiaer, E. M. (2009) · Histopathology · doi:10.1111/j.1365-2559.2009.03290.x · Cited by 136
Jung, K. H., Noh, J. H., Kim, J. K., Eun, J. W., Bae, H. J., Xie, H. J., Chang, Y. G., Kim, M., Park, H., Lee, J. Y., et al. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24090 · Cited by 135
Stypula‐Cyrus, Y., Damania, D. P., Kunte, D. P., Cruz, M. D., Subramanian, H., Roy, H. K., & Backman, V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064600 · Cited by 134
Song, C., Zhu, S., Wu, C., & Kang, J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.498758 · Cited by 133
Chen, S., Yin, C., Lao, T., Liang, D., He, D., Wang, C., & Sang, N. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1055426 · Cited by 127
A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance
Santoro, F., Botrugno, O. A., Zuffo, R. D., Pallavicini, I., Matthews, G. M., Cluse, L. A., Barozzi, I., Senese, S., Fornasari, L., Moretti, S., et al. (2013) · Blood · doi:10.1182/blood-2012-10-461988 · Cited by 125
Taylor, B. S., DeCarolis, P. L., Angeles, C. V., Brenet, F. A., Schultz, N. D., Antonescu, C. R., Scandura, J. M., Sander, C., Viale, A. J., Socci, N. D., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0181 · Cited by 125
Xie, H. J., Noh, J. H., Kim, J. K., Jung, K. H., Eun, J. W., Bae, H. J., Kim, M., Chang, Y. G., Lee, J. Y., Park, H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034265 · Cited by 125
Dong, M., Ning, Z., Xing, P.-Y., Xu, J.-L., Cao, H., Dou, G.-F., Meng, Z., Shi, Y., Lu, X., & Feng, F.-Y. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1847-5 · Cited by 122
Ouaïssi, M., Sielezneff, I., Silvestre, R., Sastre, B., Bernard, J., Simony-Lafontaine, J., Payan, M. J., Dahan, L., Pirró, N., Seitz, J. F., et al. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-9940-z · Cited by 122
Venugopal, B., Baird, R. D., Kristeleit, R. S., Plummer, R., Cowan, R. A., Stewart, A., Fourneau, N., Hellemans, P., Elsayed, Y. A., Mcclue, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0312 · Cited by 122
HDAC inhibitors still need a home run, despite recent approval
Guha, M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4583 · Cited by 120
Quint, K., Agaimy, A., Fazio, P. D., Montalbano, R., Steindorf, C., Jung, R., Hellerbrand, C., Hartmann, A., Sitter, H., Neureiter, D., et al. (2011) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-011-1103-0 · Cited by 119
Ellis, L., Bots, M. L., Lindemann, R. K., Bolden, J. E., Newbold, A., Cluse, L. A., Scott, C. L., Strasser, A., Atadja, P. W., Lowe, S. W., et al. (2009) · Blood · doi:10.1182/blood-2008-10-182758 · Cited by 118
Vasilatos, S. N., Katz, T. A., Oesterreich, S., Wan, Y., Davidson, N. E., & Huang, Y. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt033 · Cited by 118
Kaluza, D., Krøll, J., Gesierich, S., Manavski, Y., Boeckel, J., Doebele, C., Zelent, A., Rössig, L., Zeiher, A. M., Augustin, H. G., et al. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.300415 · Cited by 116
Cha, T., Chuang, M., Wu, S., Sun, G., Chang, S., Yü, D., Huang, S., Huan, S. K.-H., Cheng, T., Chen, T., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1918 · Cited by 115
Christiansen, A. J., West, A. C., Banks, K.-M., Haynes, N. M., Teng, M. W. L., Smyth, M. J., & Johnstone, R. W. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011037108 · Cited by 114
Selective HDAC1/HDAC2 Inhibitors Induce Neuroblastoma Differentiation
Frumm, S. M., Fan, Z. P., Ross, K. N., Duvall, J. R., Gupta, S., VerPlank, L., Suh, B., Holson, E. B., Wagner, F. F., Smith, W. B., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.03.020 · Cited by 114
Tang, C. C., Li, C., Zhang, S., Hu, Z., Wu, J., Dong, C., Huang, J., & Zhou, H. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00099 · Cited by 113
Hug, B. A., & Lazar, M. A. (2004) · Oncogene · doi:10.1038/sj.onc.1207674 · Cited by 112
Chen, I., Chiang, W., Huang, H.-H., Chen, P., Shen, Y., & Chiang, H. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-254 · Cited by 111
Entinostat for treatment of solid tumors and hematologic malignancies
Knipstein, J., & Gore, L. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.613822 · Cited by 110
Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis
Zhang, Y., Adachi, M., Kawamura, R., & Imai, K. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401686 · Cited by 110
Specific Activity of Class II Histone Deacetylases in Human Breast Cancer Cells
Duong, V., Bret, C., Altucci, L., Mai, A., Duraffourd, C. C., Loubersac, J., Harmand, P.-O., Bonnet, S., Valente, S., Maudelondé, T., et al. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0299 · Cited by 110
Histone Deacetylase Regulation of ATM-Mediated DNA Damage Signaling
Thurn, K. T., Thomas, S., Raha, P., Qureshi, I., & Münster, P. N. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1242 · Cited by 110
Marquard, L., Gjerdrum, L. M. R., Christensen, I. J., Jensen, P. B., Sehested, M., & Ralfkiaer, E. M. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03109.x · Cited by 109
Nakashima, H., Nguyen, T., Goins, W. F., & Chiocca, E. A. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.593871 · Cited by 109
Mishima, Y. M., Santo, L., Eda, H., Cirstea, D. D., Nemani, N., Yee, A. J., O’Donnell, E., Selig, M. K., Quayle, S. N., Arastu‐Kapur, S., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13315 · Cited by 107
Pauer, L., Olivares, J., Cunningham, C. C., Williams, A., Grove, W. R., Kraker, A. J., Olson, S. C., & Nemunaitis, J. J. (2004) · Cancer Investigation · doi:10.1081/cnv-200039852 · Cited by 106
Suzuki, T., Kasuya, Y., Itoh, Y., Ota, Y., Zhan, P., Asamitsu, K., Nakagawa, H., Okamoto, T., & Miyata, N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068669 · Cited by 105
Rhodes, L. V., Tate, C. R., Segar, H. C., Burks, H. E., Phamduy, T. B., Hoang, V. T., Elliott, S. G., Gilliam, D., Pounder, F. N., Anbalagan, M., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2979-6 · Cited by 105
Inhibition of Histone Deacetylase 3 Causes Replication Stress in Cutaneous T Cell Lymphoma
Wells, C. E., Bhaskara, S., Stengel, K. R., Zhao, Y., Sirbu, B. M., Chagot, B., Cortez, D., Khabele, D., Chazin, W., Cooper, A. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068915 · Cited by 104
Galloway, T. J., Wirth, L. J., Colevas, A. D., Gilbert, J., Bauman, J. E., Saba, N. F., Raben, D., Mehra, R., Ma, A. W., Atoyan, R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2820 · Cited by 102
Restricted mitochondrial protein acetylation initiates mitochondrial autophagy
Webster, B. R., Scott, I., Han, K., Li, J. H., Lu, Z., Stevens, M. V., Malide, D. A., Chen, Y., Samsel, L., Connelly, P. S., et al. (2013) · Journal of Cell Science · doi:10.1242/jcs.131300 · Cited by 101
Galli, M., Salmoiraghi, S., Golay, J., Gozzini, A., Crippa, C., Pescosta, N., & Rambaldi, A. (2009) · Annals of Hematology · doi:10.1007/s00277-009-0793-8 · Cited by 101
Seo, J., Min, S. K., Park, H.-R., Kim, D. H., Kwon, M. J., Kim, L. S., & Ju, Y.-S. (2014) · Journal of Breast Cancer · doi:10.4048/jbc.2014.17.4.323 · Cited by 100
Raha, P., Thomas, S., Thurn, K. T., Park, J., & Münster, P. N. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0533-z · Cited by 99
SIRT1/PARP1 crosstalk: connecting DNA damage and metabolism
Luna, A., Aladjem, M. I., & Kohn, K. W. (2013) · Genome Integrity · doi:10.1186/2041-9414-4-6 · Cited by 99
Histone Deacetylase Inhibitors Equipped with Estrogen Receptor Modulation Activity
Gryder, B. E., Rood, M. K., Johnson, K. A., Patil, V., Raftery, E. D., Yao, L.-P. D., Rice, M., Azizi, B., Doyle, D. F., & Oyelere, A. K. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400467w · Cited by 97
Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma
Ecker, J., Oehme, I., Mazitschek, R., Korshunov, A., Kool, M., Hielscher, T., Kiss, J., Selt, F., Konrad, C., Lodrini, M., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0201-7 · Cited by 96
Amengual, J. E., Johannet, P. M., Lombardo, M., Zullo, K. M., Hoehn, D., Bhagat, G., Scotto, L., Jirau-Serrano, X., Radeski, D., Heinen, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3068 · Cited by 94
Histone Deacetylases 9 and 10 Are Required for Homologous Recombination
Kotian, S., Liyanarachchi, S., Zelent, A., & Parvin, J. D. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.c110.194233 · Cited by 93
Xue, K., Gu, J. J., Zhang, Q., Mavis, C. K., Hernandez‐Ilizaliturri, F. J., Czuczman, M. S., & Guo, Y. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-015-2026-y · Cited by 92
Histone Deacetylase in Chronic Lymphocytic Leukemia
Wang, J. C., Kafeel, M. I., Avezbakiyev, B., Chen, C., Sun, Y., Rathnasabapathy, C., Kalavar, M. R., He, Z., Burton, J., & Lichter, S. (2011) · Oncology · doi:10.1159/000334577 · Cited by 92
Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity
Cao, K., Wang, G., Li, W., Zhang, L., Wang, R., Huang, Y., Du, L., Jiang, J., Wu, C., He, X., et al. (2015) · Oncogene · doi:10.1038/onc.2015.46 · Cited by 92
Murakami, T., Sato, A., Chun, N. A. L., Hara, M., Naito, Y., Kobayashi, Y., Kano, Y., Ohtsuki, M., Furukawa, Y., & Kobayashi, E. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701216 · Cited by 92
p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors
Sonnemann, J., Marx, C., Becker, S., Wittig, S., Palani, C. D., Krämer, O. H., & Beck, J. F. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.742 · Cited by 88
Zhang, X., Kong, Y., Zhang, J., Su, M., Zhou, Y., Zang, Y., Li, J. X., Chen, Y., Fang, Y., Zhang, X., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.03.035 · Cited by 87
The anticancer effects of HDAC inhibitors require the immune system
West, A. C., Smyth, M. J., & Johnstone, R. W. (2014) · OncoImmunology · doi:10.4161/onci.27414 · Cited by 87
HDAC8 and STAT3 repress BMF gene activity in colon cancer cells
Kang, Y., Nian, H., Rajendran, P., Kim, E., Dashwood, W. M., Pinto, J. T., Boardman, L. A., Thibodeau, S. N., Limburg, P. J., Löhr, C. V., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.422 · Cited by 87
Damme, M. V., Crompot, E., Meuleman, N., Mineur, P., Bron, D., Lagneaux, L., & Stamatopoulos, B. (2012) · Epigenetics · doi:10.4161/epi.22674 · Cited by 86
Ishikawa, S., Hayashi, H., Kinoshita, K., Abe, M., Kuroki, H., Tokunaga, R., Tomiyasu, S., Tanaka, H., Sugita, H., Arita, T., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28672 · Cited by 85
HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells
Schüler, S., Fritsche, P., Diersch, S., Arlt, A., Schmid, R. M., Saur, D., & Schneider, G. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-80 · Cited by 85
Shimizu, T., LoRusso, P. M., Papadopoulos, K. P., Patnaik, A., Beeram, M., Smith, L. S., Rasco, D. W., Mays, T. A., Chambers, G., Ma, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0570 · Cited by 85
Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma
Kikuchi, S., Suzuki, R., Ohguchi, H., Yoshida, Y., Lu, D., Cottini, F., Jakubíková, J., Bianchi, G., Harada, T., Görgün, G., et al. (2015) · Leukemia · doi:10.1038/leu.2015.83 · Cited by 84
Zhi, X., & Zhong, Q. (2015) · F1000Prime Reports · doi:10.12703/p7-18 · Cited by 83
Bangert, A., Cristofanon, S., Eckhardt, I., Abhari, B. A., Kolodziej, S., Häcker, S., Vellanki, S. H., Lausen, J., Debatin, K., & Fulda, S. (2012) · Oncogene · doi:10.1038/onc.2011.614 · Cited by 83
Moffat, D. F. C., Patel, S. R., Day, F. A., Belfield, A. J., Donald, A., Rowlands, M., Wibawa, J. I. D., Brotherton, D. H., Stimson, L., Clark, V., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101177s · Cited by 83
Lee, H., Tsai, A.-C., Chen, M.-C., Shen, P.-J., Cheng, Y.-C., Kuo, C., Pan, S., Liu, Y.-M., Liu, J.-F., Yeh, T., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401899x · Cited by 83
Fischer, C., Leithner, K., Wohlkoenig, C., Quehenberger, F., Bertsch, A., Olschewski, A., Olschewski, H., & Hrzenjak, A. (2015) · Molecular Cancer · doi:10.1186/1476-4598-14-4 · Cited by 83
HIPK2 restricts SIRT1 activity upon severe DNA damage by a phosphorylation-controlled mechanism
Conrad, E., Polonio-Vallon, T., Meister, M. T., Matt, S., Bitomsky, N., Herbel, C., Liebl, M. C., Greiner, V., Križnik, B., Schumacher, S. D., et al. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2015.75 · Cited by 80
Huang, W., Wang, Y., Chao, S.-W., Yang, C., Chen, L., Lin, M., Hou, W., Chen, M., Lee, T., Yang, P., et al. (2012) · ChemMedChem · doi:10.1002/cmdc.201200300 · Cited by 80
Emerging approaches for histone deacetylase inhibitor drug discovery
Zwergel, C., Valente, S., Jacob, C., & Mai, A. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1038236 · Cited by 79
Xiao, W., Chen, X., Liu, X., Luo, L., Ye, S., & Liu, Y. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12212 · Cited by 79
Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer
Poyet, C., Jentsch, B., Hermanns, T., Schweckendiek, D., Seifert, H., Schmidtpeter, M., Sulser, T., Moch, H., Wild, P. J., & Kristiansen, G. (2014) · BMC Clinical Pathology · doi:10.1186/1472-6890-14-10 · Cited by 78
Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma
Adams, H., Fritzsche, F. R., Dirnhofer, S., Kristiansen, G., & Tzankov, A. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728221003796609 · Cited by 78
Selvaraju, K., Renu, S., Krishnamoorthy, V., & Ravikumar, V. (2014) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.01.002 · Cited by 77
Koeneke, E., Witt, O., & Oehme, I. (2015) · Cells · doi:10.3390/cells4020135 · Cited by 77
Niegisch, G., Knievel, J., Koch, A., Hader, C., Fischer, U., Albers, P., & Schulz, W. A. (2012) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2012.06.015 · Cited by 77
Banerji, U., van Doorn, L., Papadatos-Pastos, D., Kristeleit, R. S., Debnam, P. M., Tall, M., Stewart, A., Raynaud, F. I., Garrett, M. D., Toal, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3165 · Cited by 77
Kim, J. K., Noh, J. H., Eun, J. W., Jung, K. H., Bae, H. J., Shen, Q., Kim, M. G., Chang, Y. G., Kim, S.-J., Park, W. S., et al. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0332 · Cited by 76
Li, Y., Peng, L., & Seto, E. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00400-15 · Cited by 76
Self-citationRiley, J. S., Hutchinson, R. A., McArt, D. G., Crawford, N., Holohan, C., Paul, I., Schaeybroeck, S. V., Salto‐Tellez, M., Johnston, P. G., Fennell, D. A., et al. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.481 · Cited by 73
Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine
Ahrens, T. D., Timme, S., Hoeppner, J., Ostendorp, J., Hembach, S., Follo, M., Hopt, U. T., Werner, M., Busch, H. S., Boerries, M., et al. (2015) · Epigenetics · doi:10.1080/15592294.2015.1039216 · Cited by 73
Fan, J., Lou, B., Chen, W., Zhang, J., Lin, S., Lv, F., & Chen, Y. (2014) · Tumor Biology · doi:10.1007/s13277-014-2358-2 · Cited by 73
Gruhn, B., Naumann, T., Gruner, D., Walther, M., Wittig, S., Becker, S., Beck, J. F., & Sonnemann, J. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.07.016 · Cited by 73
Suzuki, T., Muto, N., Bando, M., Itoh, Y., Masaki, A., Ri, M., Ota, Y., Nakagawa, H., Iida, S., Shirahige, K., et al. (2014) · ChemMedChem · doi:10.1002/cmdc.201300414 · Cited by 71
Seo, H., Kim, E., Na, H., & Lee, M. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.11.044 · Cited by 71
AsSIRTing the DNA damage response
Gorospe, M., & de Cabo, R. (2008) · Trends in Cell Biology · doi:10.1016/j.tcb.2007.11.007 · Cited by 71
Peng, L., Yuan, Z., Li, Y., Ling, H., Izumi, V., Fang, B., Fukasawa, K., Koomen, J. M., Chen, J., & Seto, E. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.612796 · Cited by 69
Self-citationMPP8 and SIRT1 crosstalk in E‐cadherin gene silencing and epithelial–mesenchymal transition
Sun, L., Kokura, K., Izumi, V., Koomen, J. M., Seto, E., Chen, J., & Fang, J. (2015) · EMBO Reports · doi:10.15252/embr.201439792 · Cited by 68
Self-citationDong, L., Cheng, S., Zheng, Z., Wang, L., Shen, Y., Shen, Z. X., Chen, S., & Zhao, W. L. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-53 · Cited by 67
A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth
Kaliszczak, M., Trousil, S., Åberg, O., Perumal, M., Nguyen, Q.-D., & Aboagye, E. O. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.576 · Cited by 66
Li, D., Sun, X., Zhang, L., Yan, B., Xie, S., Liu, R., Liu, M., & Zhou, J. (2013) · Protein & Cell · doi:10.1007/s13238-013-0010-3 · Cited by 66
Kraker, A. J., Mizzen, C. A., Hartl, B. G., Miin, J., Allis, C. D., & Merriman, R. L. (2003) · PubMed · Cited by 64
Shukla, S., Khan, S. U., Kumar, S., Sinha, S., Farhan, M., Bora, H. K., Maurya, R., & Meeran, S. M. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-14-0286 · Cited by 64
Choy, E., Flamand, Y., Balasubramanian, S., Butrynski, J. E., Harmon, D. C., George, S., Cote, G. M., Wagner, A. J., Morgan, J. A., Sirisawad, M., et al. (2014) · Cancer · doi:10.1002/cncr.29175 · Cited by 62
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Self-citationOral squamous cell carcinomas: state of the field and emerging directions
Tan, Y., Wang, Z., Xu, M., Li, B., Huang, Z., Qin, S., Nice, E. C., Tang, J., & Huang, C. (2023) · International Journal of Oral Science · doi:10.1038/s41368-023-00249-w · Cited by 831
Suraweera, A., O’Byrne, K. J., & Richard, D. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00092 · Cited by 669
Aging and age‐related diseases: from mechanisms to therapeutic strategies
Li, Z., Zhang, Z., Ren, Y., Wang, Y., Fang, J., Yue, H., Ma, S., & Guan, F. (2021) · Biogerontology · doi:10.1007/s10522-021-09910-5 · Cited by 640
Fellows, R., Denizot, J., Stellato, C., Cuomo, A., Jain, P., Stoyanova, E., Balázsi, S., Hajnády, Z., Liebert, A., Kazakevych, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02651-5 · Cited by 568
Metadata
- Authors
- Li, Y., & Seto, E.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2016-09-06
- Volume
- 6
- Issue
- 10
- Pages
- a026831
- ISSN
- 2157-1422 (ISSN-L)
- OpenAlex
- W2511667040
- Cited by
- 1,284
- References
- 265
- Type
- posted content
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.